Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Sandmann S, Unger T
L- and T-type calcium channel blockade - the efficacy of the calcium channel antagonist mibefradil
Journal of Clinical and Basic Cardiology 1999; 2 (2): 187-201

PDF    Summary    Overview   

First Image Fig. 6: Kalziumkanal - Mibefradil Fig. 7: Kalziumkanal - Mibefradil Fig. 8A-B: Kalziumkanal - Mibefradil Fig. 9: Kalziumkanal - Mibefradil Fig. 10: Kalziumkanal - Mibefradil Fig. 11: Kalziumkanal - Mibefradil This Image - Fig. 12: Kalziumkanal - Mibefradil Fig. 13: Kalziumkanal - Mibefradil
Figure/Graphic 12: Kalziumkanal - Mibefradil
Left panel: Maximal ST-segment depression in mV before (open bars) and 2 hours after (hatched bars) intake of placebo or 50, 100, or 200 mg/kg mibefradil; * p < 0.05. Right panel: Mean exercise duration in minutes before (open bars) and 2 hours after (hatched bars) intake of placebo or 50, 100, or 200 mg/kg mibefradil; * p < 0.05.
 
Kalziumkanal - Mibefradil
Previous Image Next Image   


Figure/Graphic 12: Kalziumkanal - Mibefradil
Left panel: Maximal ST-segment depression in mV before (open bars) and 2 hours after (hatched bars) intake of placebo or 50, 100, or 200 mg/kg mibefradil; * p < 0.05. Right panel: Mean exercise duration in minutes before (open bars) and 2 hours after (hatched bars) intake of placebo or 50, 100, or 200 mg/kg mibefradil; * p < 0.05.
 
copyright © 2000–2026 Krause & Pachernegg GmbH | Sitemap | Datenschutz | Impressum
 
Werbung